Recruiting

Observational Study

Sponsor:

John M. Buatti

Code:

NCT07447531

Conditions

Malignant Glioma

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

T2 (Observed)-Weighted Imaging

Biospecimen Collection

Magnetic Resonance Imaging

Study Details

Brief summary:

This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.

Conditions

Malignant Glioma

Study ID

NCT07447531

Start date

Oct 3, 2025

Status verified date

Feb, 2026

Completion date

Oct 6, 2028

Anticipated

Primary completion date

Oct 6, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age > 21 years
  • New pathologically confirmed diagnosis of WHO grade IV malignant glioma
  • KPS > 60
  • Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol

Exclusion Criteria:

  • History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
  • History of iron metabolic disorder such as hemochromatosis
  • Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices

Study Design

Enrollment

15 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Diagnostic (T2* MRI, blood sample collection)

Patients undergo T2\* MRI over 10 minutes and blood sample collection during radiation therapy simulation, weekly during radiation therapy, and at 1- and 3- months post-radiation therapy in the absence of unacceptable toxicity. Patients also undergo standard MRI throughout the study.

Interventions

T2 (Observed)-Weighted Imaging

Undergo T2\* MRI

Biospecimen Collection

Undergo blood sample collection

Magnetic Resonance Imaging

Undergo standard MRI

Primary outcome measure

  • Relationship between T2 (observed)-weighted imaging (T2*) magnetic resonance imaging relation time and dimeric transferrin receptor expression [ Time Frame: Up to 3 months post-radiation therapy ]

Central Contacts and Locations

Central contacts

John Buatti, MD

(319) 356-7590john-buatti@uiowa.edu

Locations

University of Iowa Health Care

Recruiting

Iowa City, Iowa, United States, 52245

Contacts

John Buatti, MD

319-356-7590john-buatti@uiowa.edu

John Buatti, MD

(319) 356-7590john-buatti@uiowa.edu

More Information

Sponsor

John M. Buatti

Last update posted

Mar 3, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by John M. Buatti on 2026-03-03.